Home
User Guide
What's in a MalaCard Search Guide Our Sources
Analysis Tools
GeneCards GeneAnalytics GeneAlaCart PathCards VarElect TGex
News and Views Disease Lists/Categories
About
About MalaCards Datasets Our Publications Weizmann Institute LifeMap Discovery® Terms of Use MalaCards Team
MCID: BLD131
MIFTS: 62

Bladder Urothelial Carcinoma

Categories: Cancer diseases, Nephrological diseases
Genes Variations Tissues Related diseases Publications Pathways Drugs
Sources

Aliases & Classifications for Bladder Urothelial Carcinoma

About this section

MalaCards integrated aliases for Bladder Urothelial Carcinoma:

Name: Bladder Urothelial Carcinoma 12 15
Transitional Cell Carcinoma of the Bladder 29 6
Transitional Cell Carcinoma of Bladder 12 71
Bladder Transitional Cell Carcinoma 12 17
Urinary Bladder Urothelial Carcinoma 12
Carcinoma Transitional Cell Bladder 54
Urothelial Bladder Carcinoma 12

Classifications:

MalaCards categories:
Global: Cancer diseases
Anatomical: Nephrological diseases
See all MalaCards categories (disease lists)


External Ids:

Disease Ontology 12 DOID:4006
NCIt 49 C39851
SNOMED-CT 67 255109008
UMLS 71 C0279680
Sources

Summaries for Bladder Urothelial Carcinoma

About this section
Disease Ontology : 12 A bladder carcinoma that has material basis in transitional cells located in the lining of the bladder.

MalaCards based summary : Bladder Urothelial Carcinoma, also known as transitional cell carcinoma of the bladder, is related to bladder cancer and in situ carcinoma. An important gene associated with Bladder Urothelial Carcinoma is PIK3CA (Phosphatidylinositol-4,5-Bisphosphate 3-Kinase Catalytic Subunit Alpha), and among its related pathways/superpathways are Innate Immune System and ERK Signaling. The drugs Valrubicin and Tocopherol have been mentioned in the context of this disorder. Affiliated tissues include lining of the bladder, prostate and lymph node, and related phenotypes are Decreased viability and Decreased viability

Sources

Related Diseases for Bladder Urothelial Carcinoma

About this section

Diseases related to Bladder Urothelial Carcinoma via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 497)
# Related Disease Score Top Affiliating Genes
1 bladder cancer 32.4 TUG1 TP53 PVT1 PIK3CA NRAS MEG3
2 in situ carcinoma 32.2 TP53 PIK3CA HRAS ERBB2 CTNNB1
3 transitional cell carcinoma 32.1 TP53 PIK3CA HRAS FGFR3 ERBB2 CTNNB1
4 adenoma 31.6 TP53 PIK3CA KRAS CTNNB1 BRAF
5 lynch syndrome 31.4 TP53 PIK3CA KRAS HRAS ERBB2 CTNNB1
6 renal cell carcinoma, nonpapillary 31.4 TUG1 TP53 PVT1 PIK3CA NRAS MALAT1
7 vulva cancer 31.3 TP53 PIK3CA HRAS ERBB2
8 carcinosarcoma 31.3 TP53 PIK3CA KRAS HRAS ERBB2 CTNNB1
9 thymoma 31.2 TP53 PIK3CA HRAS CTNNB1
10 signet ring cell adenocarcinoma 31.2 TP53 KRAS HRAS ERBB2 CTNNB1
11 thyroid carcinoma 31.2 PIK3CA HRAS BRAF
12 intrahepatic cholangiocarcinoma 31.2 TUG1 TP53 KRAS IDH1 ERBB2 CTNNB1
13 ureteral obstruction 31.2 TP53 NFE2L2 CTNNB1
14 nevus, epidermal 31.2 PIK3CA NRAS KRAS HRAS FGFR3 FGFR1
15 villous adenoma 31.2 TP53 KRAS HRAS BRAF
16 colorectal adenocarcinoma 31.2 TP53 KRAS HRAS ERBB2 CTNNB1 BRAF
17 cholangiocarcinoma 31.2 TUG1 TP53 PIK3CA MALAT1 KRAS IDH1
18 suppression of tumorigenicity 12 31.2 TP53 PIK3CA KRAS IDH1 HRAS FGFR1
19 large cell carcinoma 31.1 KRAS HRAS FGFR1 ERBB2
20 adenocarcinoma 31.1 TP53 PIK3CA MAP2K1 MALAT1 KRAS HRAS
21 breast cancer 31.1 TUG1 TP53 PVT1 PIK3CA NRAS MEG3
22 squamous cell carcinoma 31.1 TUG1 TP53 PIK3CA NFE2L2 MAP2K1 MALAT1
23 mucinous adenocarcinoma 31.1 TP53 KRAS ERBB2
24 squamous cell papilloma 31.1 TP53 HRAS
25 prostate cancer 31.1 TUG1 TP53 PVT1 PIK3CA NFE2L2 MEG3
26 lymphoma 31.1 TP53 PVT1 PIK3CA NRAS MAP2K1 GAS5
27 exanthem 31.1 KRAS HRAS ERBB2
28 gastric adenocarcinoma 31.0 TP53 PIK3CA NRAS KRAS IDH1 HRAS
29 pancreatic adenocarcinoma 31.0 TP53 PIK3CA MAP2K1 KRAS HRAS FGFR1
30 thyroid cancer, nonmedullary, 1 31.0 MEG3 MALAT1 HOTAIR
31 cervical cancer 30.9 TUG1 TP53 PVT1 PIK3CA NFE2L2 MEG3
32 glioma 30.9 TP53 PVT1 PIK3CA MEG3 MALAT1 IDH1
33 appendix adenocarcinoma 30.8 KRAS HRAS
34 pancreatic cancer 30.8 TUG1 TP53 PVT1 PIK3CA MEG3 MAP2K1
35 colorectal cancer 30.7 TUG1 TP53 PVT1 PIK3CA NRAS NFE2L2
36 hepatocellular carcinoma 30.7 TUG1 TP53 PVT1 PIK3CA NRAS NFE2L2
37 non-papillary transitional cell carcinoma of the bladder 12.7
38 infiltrating bladder urothelial carcinoma sarcomatoid variant 12.6
39 non-invasive bladder urothelial carcinoma 12.5
40 clear cell variant infiltrating bladder urothelial carcinoma 12.5
41 micropapillary variant infiltrating bladder urothelial carcinoma 12.5
42 lipid-cell variant infiltrating bladder urothelial carcinoma 12.5
43 plasmacytoid variant infiltrating bladder urothelial carcinoma 12.5
44 nested variant infiltrating bladder urothelial carcinoma 12.5
45 microcystic variant infiltrating bladder urothelial carcinoma 12.5
46 lymphoma-like variant infiltrating bladder urothelial carcinoma 12.4
47 invasive bladder transitional cell carcinoma 11.9
48 small cell carcinoma of the bladder 11.6
49 acanthoma 11.0 TP53 PIK3CA FGFR3
50 keratosis, seborrheic 10.9 TP53 PIK3CA FGFR3

Graphical network of the top 20 diseases related to Bladder Urothelial Carcinoma:



Diseases related to Bladder Urothelial Carcinoma
Sources

Symptoms & Phenotypes for Bladder Urothelial Carcinoma

About this section

GenomeRNAi Phenotypes related to Bladder Urothelial Carcinoma according to GeneCards Suite gene sharing:

26 (show all 34)
# Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Decreased viability GR00055-A-1 10.83 HRAS KRAS PIK3CA BRAF
2 Decreased viability GR00055-A-2 10.83 HRAS KRAS PIK3CA BRAF
3 Decreased viability GR00055-A-3 10.83 KRAS
4 Decreased viability GR00106-A-0 10.83 KRAS
5 Decreased viability GR00107-A-1 10.83 MAP2K1
6 Decreased viability GR00221-A-1 10.83 FGFR1 FGFR3 HRAS KRAS PIK3CA NRAS
7 Decreased viability GR00221-A-2 10.83 FGFR1 FGFR3 HRAS KRAS PIK3CA
8 Decreased viability GR00221-A-3 10.83 FGFR3 HRAS ERBB2 MAP2K1 NRAS
9 Decreased viability GR00221-A-4 10.83 PIK3CA BRAF ERBB2
10 Decreased viability GR00249-S 10.83 FGFR3 BRAF
11 Decreased viability GR00301-A 10.83 KRAS BRAF
12 Decreased viability GR00381-A-1 10.83 KRAS BRAF
13 Decreased viability GR00386-A-1 10.83 FGFR1
14 Decreased viability GR00402-S-2 10.83 PIK3CA
15 Decreased cell migration GR00055-A-1 9.8 FGFR3
16 Decreased cell migration GR00055-A-3 9.8 BRAF HRAS PIK3CA
17 Increased shRNA abundance (Z-score > 2) GR00366-A-100 9.6 FGFR1
18 Increased shRNA abundance (Z-score > 2) GR00366-A-112 9.6 IDH1
19 Increased shRNA abundance (Z-score > 2) GR00366-A-125 9.6 FGFR1
20 Increased shRNA abundance (Z-score > 2) GR00366-A-127 9.6 IDH1
21 Increased shRNA abundance (Z-score > 2) GR00366-A-136 9.6 IDH1
22 Increased shRNA abundance (Z-score > 2) GR00366-A-138 9.6 IDH1
23 Increased shRNA abundance (Z-score > 2) GR00366-A-149 9.6 BRAF
24 Increased shRNA abundance (Z-score > 2) GR00366-A-169 9.6 FGFR1
25 Increased shRNA abundance (Z-score > 2) GR00366-A-172 9.6 IDH1
26 Increased shRNA abundance (Z-score > 2) GR00366-A-18 9.6 IDH1
27 Increased shRNA abundance (Z-score > 2) GR00366-A-183 9.6 FGFR1
28 Increased shRNA abundance (Z-score > 2) GR00366-A-26 9.6 FGFR1
29 Increased shRNA abundance (Z-score > 2) GR00366-A-39 9.6 IDH1
30 Increased shRNA abundance (Z-score > 2) GR00366-A-43 9.6 FGFR1
31 Increased shRNA abundance (Z-score > 2) GR00366-A-47 9.6 BRAF CTNNB1 FGFR1
32 Increased shRNA abundance (Z-score > 2) GR00366-A-50 9.6 FGFR1
33 Increased shRNA abundance (Z-score > 2) GR00366-A-83 9.6 FGFR1
34 Increased focal adhesion (FA) area, decreased number of small and round FAs, increased peripheral FA formation, increased cell spreading GR00210-A 8.65 CTNNB1

MGI Mouse Phenotypes related to Bladder Urothelial Carcinoma:

45 (show all 19)
# Description MGI Source Accession Score Top Affiliating Genes
1 growth/size/body region MP:0005378 10.34 BRAF CTNNB1 ERBB2 FGFR1 FGFR3 HRAS
2 cardiovascular system MP:0005385 10.32 BRAF CTNNB1 ERBB2 FGFR1 HRAS KRAS
3 cellular MP:0005384 10.32 BRAF CTNNB1 ERBB2 FGFR1 FGFR3 KRAS
4 craniofacial MP:0005382 10.31 BRAF CTNNB1 ERBB2 FGFR1 FGFR3 HRAS
5 homeostasis/metabolism MP:0005376 10.31 BRAF CTNNB1 ERBB2 FGFR1 FGFR3 HRAS
6 digestive/alimentary MP:0005381 10.3 BRAF CTNNB1 ERBB2 FGFR1 FGFR3 HRAS
7 integument MP:0010771 10.26 BRAF CTNNB1 ERBB2 FGFR1 FGFR3 HRAS
8 embryo MP:0005380 10.25 BRAF CTNNB1 ERBB2 FGFR1 KRAS MAP2K1
9 endocrine/exocrine gland MP:0005379 10.24 BRAF CTNNB1 ERBB2 FGFR1 HRAS KRAS
10 neoplasm MP:0002006 10.17 BRAF CTNNB1 ERBB2 FGFR3 HRAS KRAS
11 nervous system MP:0003631 10.14 BRAF CTNNB1 ERBB2 FGFR1 FGFR3 HRAS
12 limbs/digits/tail MP:0005371 10.06 BRAF CTNNB1 ERBB2 FGFR1 FGFR3 KRAS
13 normal MP:0002873 10.06 BRAF CTNNB1 ERBB2 FGFR1 FGFR3 HRAS
14 hearing/vestibular/ear MP:0005377 10.05 BRAF CTNNB1 FGFR1 FGFR3 KRAS MAP2K1
15 no phenotypic analysis MP:0003012 9.97 CTNNB1 FGFR1 FGFR3 HRAS KRAS NRAS
16 renal/urinary system MP:0005367 9.86 BRAF CTNNB1 FGFR1 FGFR3 HRAS KRAS
17 respiratory system MP:0005388 9.81 BRAF CTNNB1 ERBB2 FGFR3 HRAS IDH1
18 skeleton MP:0005390 9.77 BRAF CTNNB1 ERBB2 FGFR1 FGFR3 HRAS
19 vision/eye MP:0005391 9.28 BRAF CTNNB1 FGFR1 FGFR3 KRAS MAP2K1
Sources

Drugs & Therapeutics for Bladder Urothelial Carcinoma

About this section

Drugs for Bladder Urothelial Carcinoma (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 137)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Valrubicin Approved Phase 3 56124-62-0 41744
2
Tocopherol Approved, Investigational Phase 3 1406-66-2, 54-28-4 14986
3
Amphotericin B Approved, Investigational Phase 2, Phase 3 1397-89-3 5280965 14956
4
Aminolevulinic acid Approved Phase 3 106-60-5 137
5
Lenograstim Approved, Investigational Phase 3 135968-09-1
6
Selenium Approved, Investigational, Vet_approved Phase 3 7782-49-2
7
Nicotinamide Approved, Investigational Phase 3 98-92-0 936
8
ramucirumab Approved, Investigational Phase 3 947687-13-0
9
Ciprofloxacin Approved, Investigational Phase 3 85721-33-1 2764
10
Cephalexin Approved, Investigational, Vet_approved Phase 3 15686-71-2 27447
11
Methotrexate Approved Phase 3 59-05-2, 1959-05-2 126941
12
leucovorin Approved Phase 3 58-05-9 6006 143
13
Doxorubicin Approved, Investigational Phase 3 23214-92-8 31703
14
Vinblastine Approved Phase 3 865-21-4 241903 13342
15
Gefitinib Approved, Investigational Phase 3 184475-35-2 123631
16
Vitamin E Approved, Nutraceutical, Vet_approved Phase 3 59-02-9 14985
17
Ornithine Approved, Nutraceutical Phase 3 70-26-8, 3184-13-2 6262
18
Niacin Approved, Investigational, Nutraceutical Phase 3 59-67-6 938
19
Folic acid Approved, Nutraceutical, Vet_approved Phase 3 59-30-3 6037
20 Tocotrienol Investigational Phase 3 6829-55-6
21
Levulinic acid Experimental Phase 3 123-76-2 11579
22
Fenretinide Investigational Phase 3 65646-68-6
23
BCG vaccine Investigational Phase 3
24 Tocotrienols Phase 3
25 Tocopherols Phase 3
26 Liposomal amphotericin B Phase 2, Phase 3
27 Antiparasitic Agents Phase 3
28 Antiprotozoal Agents Phase 3
29 Photosensitizing Agents Phase 3
30 Vitamins Phase 3
31 Antioxidants Phase 3
32 Protective Agents Phase 3
33 Nicotinic Acids Phase 3
34 Vitamin B3 Phase 3
35 Vasodilator Agents Phase 3
36 Lipid Regulating Agents Phase 3
37 Hypolipidemic Agents Phase 3
38 Vaccines Phase 3
39 Pharmaceutical Solutions Phase 3
40 Dermatologic Agents Phase 3
41 Cytochrome P-450 Enzyme Inhibitors Phase 3
42 Anti-Bacterial Agents Phase 3
43 Fluoroquinolones Phase 3
44 Antibiotics, Antitubercular Phase 3
45 Vitamin B Complex Phase 3
46
Liposomal doxorubicin Phase 3 31703
47 Folic Acid Antagonists Phase 3
48 Folate Phase 3
49 Vitamin B9 Phase 3
50 Adjuvants, Immunologic Phase 3

Interventional clinical trials:

(show top 50) (show all 200)
# Name Status NCT ID Phase Drugs
1 Adjuvant vs. Progression-Triggered Treatment With Gemcitabine After Radical Cystectomy for Locally Advanced Transitional Cell Carcinoma of the Bladder in Patients Not Suitable for Cisplatin-Based Chemotherapy - A Phase 3 Study Unknown status NCT00146276 Phase 3 gemcitabine
2 Phase III Randomized Study of a Single Adjunctive Instillation of Intravesical AD 32 (N-Trifluoroacetyladriamycin-14-valerate) Versus No Adjunctive Therapy Immediately Following Transurethral Resection in Patients With Multiple Superficial (Ta/T1) Bladder Tumors Unknown status NCT00003725 Phase 3 valrubicin
3 Phase III Study Of Adjuvant Cisplatin-Gemcitabine Vs. Observation After Radical Cystectomy In High-Risk Bladder Cancer Unknown status NCT00054626 Phase 3 cisplatin;gemcitabine hydrochloride
4 Bladder Cancer Prognosis Programme (Incorporating SELENIB Trial) [TREATMENT] Unknown status NCT00553345 Phase 3 selenium;vitamin E
5 Bladder Cancer Prognosis Programme (Incorporating SELENIB Trial) Unknown status NCT00553124 Phase 3 selenium;vitamin E
6 A Phase II/III, Randomised, Two-Arm, Comparison of Maintenance Lapatinib Versus Placebo After First-Line Chemotherapy in Patients With HER1 and/or HER2 Overexpressing Locally Advanced or Metastatic Bladder Cancer [LaMB] Unknown status NCT00949455 Phase 2, Phase 3 lapatinib ditosylate
7 A Laser Detection for Bladder Cancer by (Photodynamic) Spectra of Urine Completed NCT02101931 Phase 3 Amino levulinic Acid
8 Phase III Randomized, Double-Blind Study of DFMO vs. Placebo in Low Grade Superficial Bladder Cancer Completed NCT00003814 Phase 3 eflornithine
9 Megadose Vitamins as Chemoprevention of Transitional Cell Carcinoma of the Bladder Completed NCT00003623 Phase 3
10 Phase III Randomized Chemoprevention Study of Selenium on the Recurrence of Non-invasive Bladder Cancer Completed NCT00729287 Phase 3
11 Phase III Study Comparing Sequential Chemotherapy (AG-ITP) To Cisplatin And Gemcitabine As Adjuvant Treatment After Cystectomy For Transitional Cell Carcinoma Of The Bladder Completed NCT00014534 Phase 3 cisplatin;doxorubicin hydrochloride;gemcitabine hydrochloride
12 Randomised Trial of Selective Bladder Preservation Against Radical Excision (Cystectomy) in Muscle Invasive T2/T3 Transitional Cell Carcinoma of the Bladder - Feasibility Study Completed NCT00867347 Phase 3
13 A Phase III Randomized Trial of Either M-VAC or Paclitaxel + Carboplatin as Postoperative Adjuvant Therapy in Patients With Muscle-Invasive Transitional Cell Carcinoma of the Bladder at High-Risk for Relapse Completed NCT00003701 Phase 3 carboplatin;cisplatin;doxorubicin hydrochloride;methotrexate;paclitaxel;vinblastine sulfate
14 A Multicenter Randomized Trial of Radical Radiotherapy With Carbogen in the Radical Treatment of Locally Advanced Bladder Cancer Completed NCT00033436 Phase 3 carbogen
15 A RANDOMIZED TRIAL OF RADICAL RADIOTHERAPY IN pT1G3 NXM0 BLADDER CANCER Completed NCT00002490 Phase 3 mitomycin C
16 Randomized Phase III Trial Comparing Immediate Versus Deferred Chemotherapy After Radical Cystectomy in Patients With pT3-pT4, and/or N+M0 Transitional Cell Carcinoma (TCC) of the Bladder Completed NCT00028756 Phase 3 doxorubicin hydrochloride;gemcitabine hydrochloride;vinblastine sulfate;methotrexate;cisplatin
17 Phase IIb/III Chemoprevention Trial of Celecoxib to Prevent Recurrence of Superficial Bladder Cancer Completed NCT00006124 Phase 2, Phase 3 celecoxib;placebo
18 Randomized Chemoprevention Trial With 4-HPR (Fenretinide) in Superficial Bladder Cancer Completed NCT00004154 Phase 3 Fenretinide
19 2X2 Factorial Randomized Phase III Study Comparing Standard Versus Reduced Volume Radiotherapy With and Without Synchronous Chemotherapy in Muscle Invasive Bladder Cancer Completed NCT00024349 Phase 3 fluorouracil;mitomycin C
20 Randomized Phase III Study Comparing Paclitaxel/Cisplatin/Gemcitabine and Cisplatin/Gemcitabine in Patients With Metastatic or Locally Advanced Urothelial Cancer Without Prior Systemic Therapy Completed NCT00022191 Phase 3 cisplatin;gemcitabine hydrochloride;paclitaxel
21 Phase III Trial of Methotrexate, Vinblastine, Doxorubicin and Cisplatin vs Carboplatin and Paclitaxel in Advanced Carcinoma of the Urothelium Completed NCT00003376 Phase 3 carboplatin;cisplatin;doxorubicin hydrochloride;methotrexate;paclitaxel;vinblastine
22 Comparative Study of Intravesical BCG Standard Dose Long-Term Maintenance Versus BCG 1/3 Dose Long-Term Maintenance Versus BCG Standard Dose Short-Term Maintenance Versus BCG 1/3 Dose Short-Term Maintenance in Intermediate and High Risk Ta, T1 Papillary Carcinoma of the Urinary Bladder Completed NCT00002990 Phase 3
23 Cabazitaxel in Platinum Pre-treated Patients With Locally Advanced or Metastatic Transitional Cell Carcinoma Who Developed Disease Progression Within 12 Months of Platinum Based Chemotherapy. Completed NCT01668459 Phase 2, Phase 3 Cabazitaxel
24 A Phase III Blinded Study of Immediate Post TURBT Instillation of Gemcitabine Versus Saline in Patients With Newly Diagnosed or Occasionally Recurring Grade I/II Superficial Bladder Cancer Completed NCT00445601 Phase 3 gemcitabine hydrochloride
25 Randomized Phase II/III Study Assessing Gemcitabine/Carboplatin And Methotrexate/Carboplatin/Vinblastine In Previously Untreated Patients With Advanced Urothelial Cancer Ineligible For Cisplatin Based Chemotherapy Completed NCT00014274 Phase 2, Phase 3 carboplatin;gemcitabine hydrochloride;methotrexate;vinblastine sulfate
26 Sequential Bacillus Calmette-Guérin and Electromotive Mitomycin-C Versus Bacillus Calmette-Guérin Alone for High Risk Superficial Bladder Cancer: a Prospective Randomised Study Completed NCT01442519 Phase 3 electromotive mitomycin
27 S1602, A Phase III Randomized Trial to Evaluate the Influence of BCG Strain Differences and T Cell Priming With Intradermal BCG Before Intravesical Therapy for BCG-Naive High-Grade Non-muscle Invasive Bladder Cancer Recruiting NCT03091660 Phase 3
28 A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study of Ramucirumab Plus Docetaxel Versus Placebo Plus Docetaxel in Patients With Locally Advanced or Unresectable or Metastatic Urothelial Carcinoma Who Progressed on or After Platinum-Based Therapy Active, not recruiting NCT02426125 Phase 3 Ramucirumab;Docetaxel;Placebo
29 The Effect of Fluoroquinolones on the Disease-Free Interval in Patients With Stage Ta Transitional Cell Carcinoma of the Bladder Terminated NCT00003824 Phase 3 cephalexin;Ciprofloxacin
30 A Randomized, Double-Blind, Placebo-Controlled Phase 3 Multicenter Study of Immediate Postoperative Instillation of Gemcitabine in Patients With Superficial Transitional Cell Carcinoma of the Bladder Terminated NCT00191477 Phase 3 Gemcitabine;Placebo
31 A Phase III Study of IRESSA in Combination With Intravesical BCG Versus Intravesical BCG Alone in High Risk Superficial Transitional Cell Carcinoma of the Bladder Terminated NCT00352079 Phase 3 gefitinib
32 Chemoresection With 4 Weekly Intravesical Instillations Of Mitomycin C Versus Transurethral Resection (TUR) Followed By One Single Immediate Instillation Of Mitomycin C In Single, Small, Papillary Stage Ta, T1 Bladder Tumors: A Prospective Randomized Phase III Trial Terminated NCT00042887 Phase 3 mitomycin C
33 MVAC (Methotrexate, Vinblastine, Adriamycin, and Cisplatin) in Organ-Confined Bladder Cancer Based on p53 Status Terminated NCT00005047 Phase 3 cisplatin;doxorubicin hydrochloride;methotrexate;vinblastine
34 A Randomized Controlled Study Comparing Adjuvant Hyperthermia Treatment in Conjunction With Mitomycin C Versus BCG Immunotherapy (BCG) Adjuvant Treatment in Patients With Superficial Transitional Cell Carcinoma of the Bladder (STCCB) Terminated NCT00384891 Phase 3 Bacillus Calmette-Guérin
35 A Phase II Trial of Combination Cabazitaxel and Cisplatin Chemotherapy in the Neo-adjuvant Treatment of Transitional Cell Carcinoma of the Urinary Bladder Unknown status NCT01616875 Phase 2 Cabazitaxel + Cisplatin chemotherapy
36 First Line Treatment of Locally Advanced or Metastatic Urothelial Carcinoma of the Bladder With a Combination of Cisplatin-Paclitaxel-Gemcitabine Unknown status NCT00006118 Phase 2 cisplatin;gemcitabine hydrochloride;paclitaxel
37 A Phase II Study of Neoadjuvant Cisplatin and Gemcitabine Plus Sorafenib for Patients With Transitional-Cell Carcinoma of the Bladder Unknown status NCT01222676 Phase 2 cisplatin;gemcitabine hydrochloride;sorafenib tosylate
38 A Phase II Study of Tesetaxel in Subjects Previously Treated With Chemotherapy for Metastatic Transitional Cell Carcinoma of the Urothelium Unknown status NCT01215877 Phase 2 Tesetaxel
39 A Phase II Study Assessing SU-011248 in Previously Untreated Patients With Advanced Urothelial Cancer Ineligible for Cisplatin-Based Chemotherapy Unknown status NCT01118039 Phase 2 sunitinib malate
40 Bladder Cancer: Open Versus Laparoscopic or Robotic Cystectomy. A Study to Determine the Feasibility of Randomization to Open Versus Minimal Access Cystectomy in Patients With Bladder Cancer. Unknown status NCT01196403 Phase 2
41 Treatment of Patients With Transitional-Cell Carcinoma of the Urothelial Tract With Gemcitabine, Docetaxel and Filgrastim Unknown status NCT00005958 Phase 2 docetaxel;gemcitabine hydrochloride
42 Phase II Study of the Fully Human Monoclonal Antibody Against Transforming Growth Factor-beta (TGFβ) Receptor ALK1 (PF-03446962) in Relapsed or Refractory Urothelial Cancer (UC) Failing First-line Treatment. Unknown status NCT01620970 Phase 2 PF03446962
43 A Phase Ib/II Trial of ALT-801 in Combination With Cisplatin and Gemcitabine in Muscle Invasive or Metastatic Urothelial Cancer Unknown status NCT01326871 Phase 1, Phase 2 Cisplatin;Gemcitabine
44 A Phase II Study of R115777 (Zarnestra) in Superficial Transitional Cell Carcinoma of Bladder Completed NCT00047216 Phase 2 tipifarnib
45 Prospective Phase II Randomized Trial of Prostate Capsule Sparing Cystectomy and Nerve-sparing Radical Cystoprostatectomy in Men With Bladder Cancer Completed NCT01824329 Phase 2
46 A Phase 2 Study of the Aurora Kinase A Inhibitor Alisertib (MLN8237) in Patients With Relapsed or Refractory Transitional-cell Carcinoma of the Bladder and Urothelial Tract Completed NCT02109328 Phase 2 Alisertib;Paclitaxel;Placebo
47 An Open-Label, Multicenter, Randomized Phase 2 Study Evaluating the Safety and Efficacy of Docetaxel in Combination With Ramucirumab (IMC-1121B) Drug Product or IMC-18F1 or Without Investigational Therapy as Second-line Therapy in Patients With Locally Advanced or Metastatic Transitional Cell Carcinoma of the Bladder, Urethra, Ureter, or Renal Pelvis Following Disease Progression on First-line Platinum-based Therapy Completed NCT01282463 Phase 2 Docetaxel
48 Phase II Trial of Paclitaxel, Carboplatin and Gemcitabine in Patients With Locally Advanced Transitional Cell Carcinoma of the Bladder Completed NCT00136175 Phase 2 Paclitaxel;Carboplatin;Gemcitabine
49 Phase II Study of Intravesical Therapy With AD 32 in Patients With Papillary Urothelial Carcinoma or Carcinoma in Situ (CIS) Refractory to Prior Therapy With Bacillus Calmette-Guerin Completed NCT00003129 Phase 2 valrubicin
50 PHASE II TRIAL OF THE COMBINATION OF TRANSURETHRAL RESECTION AND NEOADJUVANT CHEMOTHERAPY FOR PATIENTS WITH INVASIVE UROTHELIAL TRACT TUMORS SELECTED BY STAGE AND P53 NUCLEAR EXPRESSION Completed NCT00002919 Phase 2 cisplatin;doxorubicin hydrochloride;methotrexate;vinblastine sulfate

Search NIH Clinical Center for Bladder Urothelial Carcinoma

Sources

Genetic Tests for Bladder Urothelial Carcinoma

About this section

Genetic tests related to Bladder Urothelial Carcinoma:

# Genetic test Affiliating Genes
1 Transitional Cell Carcinoma of the Bladder 29
Sources

Anatomical Context for Bladder Urothelial Carcinoma

About this section

The Foundational Model of Anatomy Ontology organs/tissues related to Bladder Urothelial Carcinoma:

19
Lining Of The Bladder

MalaCards organs/tissues related to Bladder Urothelial Carcinoma:

40
Prostate, Lymph Node, Testes, Kidney, Lung, Brain, Bone
Sources

Publications for Bladder Urothelial Carcinoma

About this section

Articles related to Bladder Urothelial Carcinoma:

(show top 50) (show all 2712)
# Title Authors PMID Year
1
Predictive value of p53 and pRb expression in superficial bladder cancer patients treated with BCG and interferon-alpha. 61 54
17311305 2007
2
Adenoviral receptor expression of normal bladder and transitional cell carcinoma of the bladder. 61 54
17293658 2007
3
Vascular endothelial growth factor-C (VEGF-C) expression predicts lymph node metastasis of transitional cell carcinoma of the bladder. 54 61
15733109 2005
4
[Multivariate analysis of recurrence and progression in stage T1 transitional-cell carcinoma of the bladder. Prognostic value of p53 and Ki67]. 54 61
12731328 2003
5
Structural alteration of p53 protein in patients with muscle invasive bladder transitional cell carcinoma. 61 54
11696726 2001
6
Expression of pS2 protein and its relation with the Ki-67 proliferative indices and tumor recurrence in superficial bladder carcinomas. 61 54
11528193 2001
7
E-cadherin immunostaining of bladder transitional cell carcinoma, carcinoma in situ and lymph node metastases with long-term followup. 61 54
11342899 2001
8
The role of bcl-2, p53, and ki-67 index in predicting tumor recurrence for low grade superficial transitional cell bladder carcinoma. 61 54
10687971 2000
9
Expression of the human erythrocyte glucose transporter in transitional cell carcinoma of the bladder. 61 54
10699635 2000
10
p53 and c-jun expression in urinary bladder transitional cell carcinoma: correlation with proliferating cell nuclear antigen (PCNA) histological grade and clinical stage. 54 61
9187909 1997
11
[Detection and clinical pathological significance of the expression of P21, P185, p53 proteins and mutation of ras, p53 genes in transitional cell carcinoma of the bladder]. 54 61
9275651 1996
12
Expression of p53 product in Chinese human bladder carcinoma. 61 54
7688167 1993
13
Disseminated Bacillus Calmette-Guérin Infection Detected on FDG PET/CT Following Intravesical Bacillus Calmette-Guérin Therapy. 61
32433172 2020
14
Differential Effect of Sex on Outcomes after Radical Surgery for Upper Tract and Bladder Urothelial Carcinoma: A Systematic Review and Meta-Analysis. 61
31995432 2020
15
Prognostic value of T1 substaging on oncological outcomes in patients with non-muscle-invasive bladder urothelial carcinoma: a systematic literature review and meta-analysis. 61
31493109 2020
16
Establishment of diagnostic criteria for upper urinary tract urothelial carcinoma based on genome-wide DNA methylation analysis. 61
32498593 2020
17
Narrow-band imaging assisted cystoscopy in the follow-up of patients with transitional cell carcinoma of the bladder: a randomized study in comparison with white light cystoscopy. 61
31471739 2020
18
Yolk sac tumor differentiation in urothelial carcinoma of the urinary bladder: a case report and differential diagnosis. 61
32493368 2020
19
Relevance of concurrent hypercalcemia in ureteric sarcoidosis complicated with bladder urothelial carcinoma: a case report. 61
32571234 2020
20
Radical Cystectomy and Ileal Conduit Diversion for Bladder Urothelial Carcinoma With Sarcomatoid and Squamous Variants After Renal Transplantation. 61
32499976 2020
21
Acetyl-CoA synthetase 3 promotes bladder cancer cell growth under metabolic stress. 61
32398651 2020
22
Expression of cancer stem cells markers in urinary bladder urothelial carcinoma and its precursor lesions. 61
32424373 2020
23
SLC12A5 interacts and enhances SOX18 activity to promote bladder urothelial carcinoma progression via upregulating MMP7. 61
32449280 2020
24
Expression and prognostic significance of pyruvate dehydrogenase kinase 1 in bladder urothelial carcinoma. 61
32388719 2020
25
[Algorithms for systemic therapy of prostate cancer, transitional cell carcinoma and renal cell carcinoma]. 61
32300817 2020
26
Ex-vivo Imaging of Upper Tract Urothelial Carcinoma Using Novel pH Low Insertion Peptide (Variant 3), a Molecular Imaging Probe. 61
30659902 2020
27
Enterovesical fistula secondary to transitional cell carcinoma of the bladder in a 20 years old patient: A rare entity. 61
32025495 2020
28
Down-regulation of FTO promotes proliferation and migration, and protects bladder cancer cells from cisplatin-induced cytotoxicity. 61
32299393 2020
29
Identifying Potential Prognostic Markers for Muscle-Invasive Bladder Urothelial Carcinoma by Weighted Gene Co-Expression Network Analysis. 61
31011911 2020
30
Multi-omics analysis of tumor mutation burden combined with immune infiltrates in bladder urothelial carcinoma. 61
31596511 2020
31
Analyzing the prognostic value of DKK1 expression in human cancers based on bioinformatics. 61
32411775 2020
32
Moesin (MSN) as a Novel Proteome-Based Diagnostic Marker for Early Detection of Invasive Bladder Urothelial Carcinoma in Liquid-Based Cytology. 61
32326232 2020
33
Blood Myeloid-Derived Suppressor Cells Correlate with Neutrophil-to-Lymphocyte Ratio and Overall Survival in Metastatic Urothelial Carcinoma. 61
32207064 2020
34
Expression profile and bioinformatics analysis of COMMD10 in BALB/C mice and human. 61
30787448 2020
35
Impact of Gene Polymorphisms in GAS5 on Urothelial Cell Carcinoma Development and Clinical Characteristics. 61
32354045 2020
36
Phenotypical and potential functional characteristics of different immune cells expressing CD28H/B7-H5 and their relationship with cancer prognosis. 61
31901178 2020
37
Coexistent Dedifferentiated Endometrioid Carcinoma of the Uterus and Adenocarcinoma of the Bladder in Lynch Syndrome: Case Report and Review of the Literature. 61
32167968 2020
38
The clinicopathological characteristics and prognostic value of squamous differentiation in patients with bladder urothelial carcinoma: a meta-analysis. 61
31011874 2020
39
Patient-reported Quality of Life Outcomes in Patients Treated for Muscle-invasive Bladder Cancer with Radiotherapy ± Chemotherapy in the BC2001 Phase III Randomised Controlled Trial. 61
31843338 2020
40
Targeting FGFR in bladder cancer: ready for clinical practice? 61
31671027 2020
41
SPAG5-AS1 inhibited autophagy and aggravated apoptosis of podocytes via SPAG5/AKT/mTOR pathway. 61
31957155 2020
42
Case Study: Landscape of Chimeric RNAs in Bladder Cancer. 61
31728975 2020
43
Trends in epidural anesthesia use at the time of radical cystectomy and its association with perioperative and survival outcomes: a population-based analysis. 61
32211451 2020
44
Evaluation of PD-L1 and other immune markers in bladder urothelial carcinoma stratified by histologic variants and molecular subtypes. 61
31996725 2020
45
[Interest of reTURB for pTa high grade bladder urothelial carcinoma]. 61
31866142 2020
46
Identification of Prognostic Immune Genes in Bladder Urothelial Carcinoma. 61
32420368 2020
47
A radiogenomics signature for predicting the clinical outcome of bladder urothelial carcinoma. 61
31396730 2020
48
Identification of five long noncoding RNAs signature and risk score for prognosis of bladder urothelial carcinoma. 61
31373406 2020
49
Amplification-driven BCL6-suppressed cytostasis is mediated by transrepression of FOXO3 and post-translational modifications of FOXO3 in urinary bladder urothelial carcinoma. 61
31903146 2020
50
Slingshot homolog-1 expression is a poor prognostic factor of pT1 bladder urothelial carcinoma after transurethral resection. 61
31965287 2020
Sources

Variations for Bladder Urothelial Carcinoma

About this section

ClinVar genetic disease variations for Bladder Urothelial Carcinoma:

6 (show top 50) (show all 276) ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎
# Gene Name Type Significance ClinVarId dbSNP ID GRCh37 Pos GRCh38 Pos
1 TP53 NM_000546.6(TP53):c.742C>T (p.Arg248Trp)SNV Pathogenic 12347 rs121912651 17:7577539-7577539 17:7674221-7674221
2 TP53 NM_001126112.2(TP53):c.733G>T (p.Gly245Cys)SNV Pathogenic 12349 rs28934575 17:7577548-7577548 17:7674230-7674230
3 TP53 NM_001126112.2(TP53):c.725G>A (p.Cys242Tyr)SNV Pathogenic 12354 rs121912655 17:7577556-7577556 17:7674238-7674238
4 TP53 NM_000546.6(TP53):c.743G>A (p.Arg248Gln)SNV Pathogenic 12356 rs11540652 17:7577538-7577538 17:7674220-7674220
5 TP53 NM_000546.6(TP53):c.733G>A (p.Gly245Ser)SNV Pathogenic 12365 rs28934575 17:7577548-7577548 17:7674230-7674230
6 TP53 NM_001126112.2(TP53):c.659A>C (p.Tyr220Ser)SNV Pathogenic 12383 rs121912666 17:7578190-7578190 17:7674872-7674872
7 HRAS NM_005343.4(HRAS):c.34G>A (p.Gly12Ser)SNV Pathogenic 12602 rs104894229 11:534289-534289 11:534289-534289
8 HRAS NM_005343.4(HRAS):c.35G>C (p.Gly12Ala)SNV Pathogenic 12603 rs104894230 11:534288-534288 11:534288-534288
9 HRAS NM_005343.4(HRAS):c.37G>T (p.Gly13Cys)SNV Pathogenic 12606 rs104894228 11:534286-534286 11:534286-534286
10 HRAS NM_005343.4(HRAS):c.34G>T (p.Gly12Cys)SNV Pathogenic 12613 rs104894229 11:534289-534289 11:534289-534289
11 PIK3CA NM_006218.4(PIK3CA):c.3140A>G (p.His1047Arg)SNV Pathogenic 13652 rs121913279 3:178952085-178952085 3:179234297-179234297
12 PIK3CA NM_006218.4(PIK3CA):c.3140A>T (p.His1047Leu)SNV Pathogenic 13653 rs121913279 3:178952085-178952085 3:179234297-179234297
13 TP53 NM_000546.6(TP53):c.818G>A (p.Arg273His)SNV Pathogenic 12366 rs28934576 17:7577120-7577120 17:7673802-7673802
14 PIK3CA NM_006218.4(PIK3CA):c.1633G>A (p.Glu545Lys)SNV Pathogenic 13655 rs104886003 3:178936091-178936091 3:179218303-179218303
15 PIK3CA NM_006218.4(PIK3CA):c.1634A>C (p.Glu545Ala)SNV Pathogenic 13659 rs121913274 3:178936092-178936092 3:179218304-179218304
16 NRAS NM_002524.5(NRAS):c.182A>G (p.Gln61Arg)SNV Pathogenic 13900 rs11554290 1:115256529-115256529 1:114713908-114713908
17 NRAS NM_002524.5(NRAS):c.38G>A (p.Gly13Asp)SNV Pathogenic 13901 rs121434596 1:115258744-115258744 1:114716123-114716123
18 BRAF NM_004333.6(BRAF):c.1405G>C (p.Gly469Arg)SNV Pathogenic 13970 rs121913357 7:140481403-140481403 7:140781603-140781603
19 BRAF NM_001374258.1(BRAF):c.1526G>C (p.Gly509Ala)SNV Pathogenic 13971 rs121913355 7:140481402-140481402 7:140781602-140781602
20 BRAF NM_001374258.1(BRAF):c.1901A>G (p.Asp634Gly)SNV Pathogenic 13972 rs121913338 7:140453154-140453154 7:140753354-140753354
21 BRAF NM_001374258.1(BRAF):c.1526G>A (p.Gly509Glu)SNV Pathogenic 13974 rs121913355 7:140481402-140481402 7:140781602-140781602
22 PIK3CA NM_006218.4(PIK3CA):c.3139C>T (p.His1047Tyr)SNV Pathogenic 39705 rs121913281 3:178952084-178952084 3:179234296-179234296
23 BRAF NM_001374258.1(BRAF):c.1907G>T (p.Gly636Val)SNV Pathogenic 40387 rs397507483 7:140453148-140453148 7:140753348-140753348
24 FGFR3 NM_001163213.1(FGFR3):c.742C>T (p.Arg248Cys)SNV Pathogenic 16332 rs121913482 4:1803564-1803564 4:1801837-1801837
25 FGFR3 NM_001163213.1(FGFR3):c.746C>G (p.Ser249Cys)SNV Pathogenic 16339 rs121913483 4:1803568-1803568 4:1801841-1801841
26 BRAF NM_001374258.1(BRAF):c.1526G>T (p.Gly509Val)SNV Pathogenic 44803 rs121913355 7:140481402-140481402 7:140781602-140781602
27 PIK3CA NM_006218.4(PIK3CA):c.1637A>G (p.Gln546Arg)SNV Pathogenic 45466 rs397517201 3:178936095-178936095 3:179218307-179218307
28 TP53 NM_000546.6(TP53):c.659A>G (p.Tyr220Cys)SNV Pathogenic 127819 rs121912666 17:7578190-7578190 17:7674872-7674872
29 TP53 NM_000546.6(TP53):c.638G>A (p.Arg213Gln)SNV Pathogenic 135359 rs587778720 17:7578211-7578211 17:7674893-7674893
30 TP53 NM_001126112.2(TP53):c.844C>G (p.Arg282Gly)SNV Pathogenic 140821 rs28934574 17:7577094-7577094 17:7673776-7673776
31 TP53 NM_001126112.2(TP53):c.842A>G (p.Asp281Gly)SNV Pathogenic 141141 rs587781525 17:7577096-7577096 17:7673778-7673778
32 IDH1 NM_001282386.1(IDH1):c.395G>A (p.Arg132His)SNV Pathogenic 156444 rs121913500 2:209113112-209113112 2:208248388-208248388
33 TP53 NM_001126112.2(TP53):c.856G>A (p.Glu286Lys)SNV Pathogenic 183752 rs786201059 17:7577082-7577082 17:7673764-7673764
34 TP53 NM_001126112.2(TP53):c.374C>A (p.Thr125Lys)SNV Pathogenic 216465 rs786201057 17:7579313-7579313 17:7675995-7675995
35 TP53 NM_001126112.2(TP53):c.743G>T (p.Arg248Leu)SNV Pathogenic 230253 rs11540652 17:7577538-7577538 17:7674220-7674220
36 TP53 NM_001126112.2(TP53):c.743G>C (p.Arg248Pro)SNV Pathogenic 237954 rs11540652 17:7577538-7577538 17:7674220-7674220
37 NRAS NM_002524.5(NRAS):c.182A>C (p.Gln61Pro)SNV Pathogenic 280409 rs11554290 1:115256529-115256529 1:114713908-114713908
38 NRAS NM_002524.5(NRAS):c.183A>T (p.Gln61His)SNV Pathogenic 373003 rs121913255 1:115256528-115256528 1:114713907-114713907
39 PIK3CA NM_006218.4(PIK3CA):c.1357G>A (p.Glu453Lys)SNV Pathogenic 376470 rs1057519925 3:178928079-178928079 3:179210291-179210291
40 TP53 NM_001126112.2(TP53):c.713G>T (p.Cys238Phe)SNV Pathogenic 376574 rs730882005 17:7577568-7577568 17:7674250-7674250
41 TP53 NM_001126112.2(TP53):c.713G>C (p.Cys238Ser)SNV Pathogenic 376575 rs730882005 17:7577568-7577568 17:7674250-7674250
42 TP53 NM_001126112.2(TP53):c.712T>C (p.Cys238Arg)SNV Pathogenic 376576 rs1057519981 17:7577569-7577569 17:7674251-7674251
43 PIK3CA NM_006218.4(PIK3CA):c.2176G>A (p.Glu726Lys)SNV Pathogenic 376476 rs867262025 3:178938934-178938934 3:179221146-179221146
44 TP53 NM_001126112.2(TP53):c.841G>T (p.Asp281Tyr)SNV Pathogenic 376585 rs764146326 17:7577097-7577097 17:7673779-7673779
45 TP53 NM_001126112.2(TP53):c.841G>A (p.Asp281Asn)SNV Pathogenic 376586 rs764146326 17:7577097-7577097 17:7673779-7673779
46 TP53 NM_001126112.2(TP53):c.578A>C (p.His193Pro)SNV Pathogenic 376612 rs786201838 17:7578271-7578271 17:7674953-7674953
47 TP53 NM_001126112.2(TP53):c.523C>G (p.Arg175Gly)SNV Pathogenic 376649 rs138729528 17:7578407-7578407 17:7675089-7675089
48 TP53 NM_001126112.2(TP53):c.818G>T (p.Arg273Leu)SNV Pathogenic 376655 rs28934576 17:7577120-7577120 17:7673802-7673802
49 TP53 NM_001126112.2(TP53):c.722C>A (p.Ser241Tyr)SNV Pathogenic 376663 rs28934573 17:7577559-7577559 17:7674241-7674241
50 TP53 NM_001126112.2(TP53):c.817C>A (p.Arg273Ser)SNV Pathogenic/Likely pathogenic 376656 rs121913343 17:7577121-7577121 17:7673803-7673803
Sources

Expression for Bladder Urothelial Carcinoma

About this section
Search GEO for disease gene expression data for Bladder Urothelial Carcinoma.
Sources

Pathways for Bladder Urothelial Carcinoma

About this section

Pathways related to Bladder Urothelial Carcinoma according to GeneCards Suite gene sharing:

(show top 50) (show all 164)
# Super pathways Score Top Affiliating Genes
1
Innate Immune System 65
Show member pathways
 14.18 TP53 PIK3CA NRAS MAP2K1 KRAS IDH1
2
ERK Signaling 63
Show member pathways
 13.97 TP53 NRAS MAP2K1 KRAS HRAS FGFR3
3
HIV Life Cycle 65
Show member pathways
 13.87 PIK3CA NRAS MAP2K1 KRAS IDH1 HRAS
4
GPCR Pathway 63
Show member pathways
 13.83 TP53 NRAS MAP2K1 KRAS HRAS FGFR3
5
PEDF Induced Signaling 63
Show member pathways
 13.81 TP53 NRAS MAP2K1 KRAS HRAS FGFR3
6
Activation of cAMP-Dependent PKA 63
Show member pathways
 13.7 NRAS MAP2K1 KRAS HRAS FGFR3 FGFR1
7
TGF-Beta Pathway 63
Show member pathways
 13.7 TP53 PIK3CA NRAS MAP2K1 KRAS HRAS
8
Developmental Biology 65
Show member pathways
 13.66 PIK3CA NRAS MAP2K1 KRAS HRAS FGFR3
9
Class I MHC mediated antigen processing and presentation 65
Show member pathways
 13.59 TP53 PIK3CA NRAS KRAS HRAS FGFR3
10
Cytokine Signaling in Immune system 65
Show member pathways
 13.53 TP53 PIK3CA NRAS MAP2K1 KRAS HRAS
11
CREB Pathway 63
Show member pathways
 13.45 NRAS MAP2K1 KRAS HRAS FGFR3 FGFR1
12
Nanog in Mammalian ESC Pluripotency 63
Show member pathways
 13.44 NRAS MAP2K1 KRAS HRAS FGFR3 FGFR1
13
PAK Pathway 63
Show member pathways
 13.43 NRAS KRAS HRAS FGFR3 FGFR1 ERBB2
14
IL-2 Pathway 63
Show member pathways
 13.35 TP53 NRAS MAP2K1 KRAS HRAS ERBB2
15
Parkinson disease 36
Show member pathways
 13.34 TP53 PIK3CA NRAS NFE2L2 MAP2K1 KRAS
16
Phospholipase-C Pathway 63
Show member pathways
 13.24 TP53 NRAS MAP2K1 KRAS HRAS FGFR3
17
Toll-like Receptor Signaling Pathway 36 1
Show member pathways
 13.23 TP53 PIK3CA NRAS MAP2K1 KRAS HRAS
18
TNFR1 Pathway 63
Show member pathways
 13.22 TP53 PIK3CA NRAS MAP2K1 KRAS HRAS
19
p70S6K Signaling 63
Show member pathways
 13.18 NRAS MAP2K1 KRAS HRAS FGFR3 FGFR1
20
G-Beta Gamma Signaling 63
Show member pathways
 13.16 NRAS MAP2K1 KRAS HRAS CTNNB1 BRAF
21
fMLP Pathway 63
Show member pathways
 13.16 TP53 NRAS MAP2K1 KRAS HRAS CTNNB1
22
PI3K-Akt signaling pathway 36
Show member pathways
 13.15 TP53 PIK3CA NRAS MAP2K1 KRAS HRAS
23
Human cytomegalovirus infection 36
Show member pathways
 13.11 TP53 PIK3CA NRAS MAP2K1 KRAS HRAS
24
Regulation of lipid metabolism Insulin signaling-generic cascades 22
Show member pathways
 13.08 PIK3CA NRAS MAP2K1 KRAS HRAS ERBB2
25
Focal Adhesion 36 1
Show member pathways
 13.08 PIK3CA NRAS MAP2K1 KRAS HRAS ERBB2
26
Sertoli-Sertoli Cell Junction Dynamics 63
Show member pathways
 13.07 NRAS MAP2K1 KRAS HRAS CTNNB1 BRAF
27
Aldosterone synthesis and secretion 36
Show member pathways
 13.05 NRAS MAP2K1 KRAS HRAS CTNNB1 BRAF
28
NFAT and Cardiac Hypertrophy 63
Show member pathways
 13.05 PIK3CA NRAS MAP2K1 KRAS HRAS FGFR3
29
MAPK Erk Pathway 66
Show member pathways
 13.03 PIK3CA NRAS MAP2K1 KRAS HRAS BRAF
30
CCR5 Pathway in Macrophages 63
Show member pathways
 13.03 PIK3CA NRAS MAP2K1 KRAS HRAS BRAF
31
Downstream signaling of activated FGFR2 65
Show member pathways
 13.02 PIK3CA NRAS KRAS HRAS FGFR3 FGFR1
32
Endometrial cancer 36
Show member pathways
 13.02 TP53 PIK3CA NRAS MAP2K1 KRAS HRAS
33
Development Angiotensin activation of ERK 22
Show member pathways
 13.01 PIK3CA NRAS MAP2K1 KRAS HRAS BRAF
34
Beta-Adrenergic Signaling 63
Show member pathways
 12.96 NRAS MAP2K1 KRAS HRAS CTNNB1 BRAF
35
MAPK signaling pathway 36 1
12.94 TP53 NRAS MAP2K1 KRAS HRAS FGFR3
36
Downstream signaling events of B Cell Receptor (BCR) 65
Show member pathways
 12.92 TP53 PIK3CA NRAS KRAS HRAS FGFR3
37
Common Cytokine Receptor Gamma-Chain Family Signaling Pathways 64
Show member pathways
 12.9 PIK3CA MAP2K1 KRAS HRAS BRAF
38
Ras signaling pathway 36
Show member pathways
 12.9 PIK3CA NRAS MAP2K1 KRAS HRAS FGFR3
39
Circadian entrainment 36
Show member pathways
 12.89 PIK3CA NRAS MAP2K1 KRAS HRAS
40
Apoptosis Modulation and Signaling 1
Show member pathways
 12.88 TP53 PIK3CA NRAS MAP2K1 KRAS HRAS
41
Development HGF signaling pathway 22
Show member pathways
 12.88 TP53 PIK3CA NRAS MAP2K1 KRAS HRAS
42
4-1BB Pathway 63
Show member pathways
 12.85 TP53 NRAS MAP2K1 KRAS HRAS BRAF
43
Glioma 36
Show member pathways
 12.84 TP53 PIK3CA NRAS MAP2K1 KRAS HRAS
44
Gastric cancer 36
Show member pathways
 12.84 TP53 PIK3CA NRAS NFE2L2 MAP2K1 KRAS
45
Regulation of actin cytoskeleton 36 1
12.83 PIK3CA NRAS MAP2K1 KRAS HRAS FGFR3
46
Development Endothelin-1/EDNRA signaling 22
Show member pathways
 12.82 PIK3CA NRAS MAP2K1 KRAS HRAS CTNNB1
47
Relaxin signaling pathway 36
Show member pathways
 12.81 PIK3CA NRAS MAP2K1 KRAS HRAS
48
G-AlphaQ Signaling 63
Show member pathways
 12.8 NRAS MAP2K1 KRAS HRAS BRAF
49
Immune response IL-23 signaling pathway 22
Show member pathways
 12.79 TP53 PIK3CA NRAS KRAS HRAS ERBB2
50
ErbB signaling pathway 36 1
Show member pathways
 12.78 TP53 PIK3CA NRAS MAP2K1 KRAS HRAS
Sources

GO Terms for Bladder Urothelial Carcinoma

About this section

Biological processes related to Bladder Urothelial Carcinoma according to GeneCards Suite gene sharing:

(show all 27)
# Name GO ID Score Top Affiliating Genes
1 phosphorylation GO:0016310 10.02 PIK3CA MAP2K1 FGFR3 FGFR1 ERBB2 BRAF
2 protein phosphorylation GO:0006468 9.95 PIK3CA MAP2K1 FGFR3 FGFR1 ERBB2 BRAF
3 heart development GO:0007507 9.93 TP53 MAP2K1 ERBB2 CTNNB1
4 positive regulation of ERK1 and ERK2 cascade GO:0070374 9.9 MAP2K1 HRAS FGFR3 BRAF
5 regulation of cell proliferation GO:0042127 9.89 TP53 FGFR1 CTNNB1 BRAF
6 positive regulation of cell proliferation GO:0008284 9.88 KRAS HRAS FGFR3 FGFR1 ERBB2 CTNNB1
7 negative regulation of gene expression GO:0010629 9.83 TP53 MAP2K1 HRAS FGFR1 CTNNB1
8 liver development GO:0001889 9.81 PIK3CA KRAS HRAS
9 positive regulation of protein kinase B signaling GO:0051897 9.81 PIK3CA FGFR3 FGFR1 ERBB2
10 positive regulation of kinase activity GO:0033674 9.79 FGFR3 FGFR1 ERBB2
11 cellular response to drug GO:0035690 9.76 TP53 NFE2L2 BRAF
12 negative regulation of neuron apoptotic process GO:0043524 9.76 PIK3CA KRAS HRAS BRAF
13 thymus development GO:0048538 9.67 MAP2K1 CTNNB1 BRAF
14 Ras protein signal transduction GO:0007265 9.67 TP53 NRAS KRAS HRAS
15 peptidyl-tyrosine phosphorylation GO:0018108 9.65 MAP2K1 FGFR3 FGFR1 ERBB2 BRAF
16 positive regulation of production of miRNAs involved in gene silencing by miRNA GO:1903800 9.62 TP53 MAP2K1
17 positive regulation of MAP kinase activity GO:0043406 9.62 KRAS HRAS FGFR1 ERBB2
18 lung-associated mesenchyme development GO:0060484 9.61 FGFR1 CTNNB1
19 positive regulation of phospholipase activity GO:0010518 9.61 FGFR3 FGFR1
20 regulation of axon regeneration GO:0048679 9.58 MAP2K1 BRAF
21 positive regulation of transcription from RNA polymerase II promoter in response to stress GO:0036003 9.57 TP53 NFE2L2
22 response to isolation stress GO:0035900 9.56 KRAS HRAS
23 positive regulation of gene expression GO:0010628 9.56 TP53 NFE2L2 MAP2K1 KRAS HRAS ERBB2
24 positive regulation of MAPK cascade GO:0043410 9.55 HRAS FGFR3 FGFR1 ERBB2 CTNNB1
25 positive regulation of transcription from RNA polymerase II promoter in response to hypoxia GO:0061419 9.54 TP53 NFE2L2
26 trachea formation GO:0060440 9.52 MAP2K1 CTNNB1
27 MAPK cascade GO:0000165 9.23 NRAS MAP2K1 KRAS HRAS FGFR3 FGFR1

Molecular functions related to Bladder Urothelial Carcinoma according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 kinase activity GO:0016301 9.73 PIK3CA MAP2K1 FGFR3 FGFR1 ERBB2 BRAF
2 protein C-terminus binding GO:0008022 9.67 MAP2K1 HRAS ERBB2 CTNNB1
3 nucleotide binding GO:0000166 9.61 PIK3CA NRAS MAP2K1 KRAS HRAS FGFR3
4 GDP binding GO:0019003 9.58 NRAS KRAS HRAS
5 transmembrane receptor protein tyrosine kinase activity GO:0004714 9.5 FGFR3 FGFR1 ERBB2
6 fibroblast growth factor-activated receptor activity GO:0005007 9.16 FGFR3 FGFR1
7 protein tyrosine kinase activity GO:0004713 9.02 MAP2K1 FGFR3 FGFR1 ERBB2 BRAF
Sources

Sources for Bladder Urothelial Carcinoma

About this section
3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
28 GO
29 GTR
30 HMDB
31 HPO
32 ICD10
33 ICD10 via Orphanet
34 ICD9CM
35 IUPHAR
36 KEGG
37 LifeMap
39 LOVD
41 MedGen
43 MeSH
44 MESH via Orphanet
45 MGI
48 NCI
49 NCIt
50 NDF-RT
53 NINDS
54 Novoseek
56 OMIM
57 OMIM via Orphanet
61 PubMed
63 QIAGEN
68 SNOMED-CT via HPO
69 TGDB
70 Tocris
71 UMLS
72 UMLS via Orphanet
The MalaCards human disease database index: 1-9 A B C D E F G H I J K L M N O P Q R S T U V W X Y Z
Content
Loading form....